Session » Epidemiology & Public Health Poster III: Other Rheumatic & Musculoskeletal Diseases (1022–1060)

Date: Monday, November 8, 2021

Time: 8:30AM-10:30AM

Meeting: ACR Convergence 2021

8:30AM-10:30AM: Abstract Number: 1032

Causes of Death Among Populations with Systemic Lupus Erythematosus by Race and Ethnicity

8:30AM-10:30AM: Abstract Number: 1056

Characterization of the Patterns of Care, Access and Direct Costs of Systemic Lupus Erythematosus in Brazil: Findings from the Macunaíma Study

8:30AM-10:30AM: Abstract Number: 1031

Clinical and Humanistic Burden of Dermatomyositis and Polymyositis in the United States: A Systematic Literature Review

8:30AM-10:30AM: Abstract Number: 1045

Composition of Phospholipid Fatty Acids in Erythrocyte Membranes from Patients with Ankylosing Spondylitis

8:30AM-10:30AM: Abstract Number: 1030

Critical Illness in Modern Rheumatology: Analysis of Admissions to Australian and New Zealand ICUs

8:30AM-10:30AM: Abstract Number: 1041

Do Cancer Risks Increased in the Five Major Autoimmune Diseases? A Large Cohort Study in China

8:30AM-10:30AM: Abstract Number: 1050

Epidemiology and Clinical Features of Ophthalmological Manifestations in Behçet’s Disease: Study of 50 Patients of a Series of 120 Patients in a Region in Northern Spain

8:30AM-10:30AM: Abstract Number: 1027

Epidemiology of Latent Tuberculosis Infection in Patients with Rheumatic Immune-mediated Diseases: Single University Study of 1117 Patients

8:30AM-10:30AM: Abstract Number: 1048

Estimating the Weight of Rheumatologic Diseases in Mortality in Spain: Basic Cause of Death vs Multiple Cause Analysis

8:30AM-10:30AM: Abstract Number: 1029

Evaluation of the EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus in a Population-Based Registry

8:30AM-10:30AM: Abstract Number: 1047

Exposure to Industrial Pollutants and Mortality Due to Inmune-mediated Inflammatory Systemic Diseases (IMD) in Spain

8:30AM-10:30AM: Abstract Number: 1026

Factors Impacting Likelihood of Discontinuing Immunosuppression in Adult Dermatomyositis: A Single-Center Study

8:30AM-10:30AM: Abstract Number: 1052

Female Reproductive Factors and Risk of Joint Replacement Arthroplasty of the Knee and Hip Due to Osteoarthritis in Postmenopausal Women: A Nationwide Cohort Study of 1.36 Million Women

8:30AM-10:30AM: Abstract Number: 1039

Healthcare Resource Utilization and Costs of Dermatomyositis and Polymyositis in the United States: A Systematic Literature Review

8:30AM-10:30AM: Abstract Number: 1055

How to Optimize E-Recruitment Strategies: Lessons Learned from over 3000 Participants in an International Arab Online Study

8:30AM-10:30AM: Abstract Number: 1057

Impact of Osteoarthritis in Younger Adults

8:30AM-10:30AM: Abstract Number: 1022

Incidence of Antisynthetase Syndrome and Risk of Malignancy in a Population-based Cohort (1998-2019)

8:30AM-10:30AM: Abstract Number: 1028

Knee Osteoarthritis and Mortality: The Osteoarthritic Initiative

8:30AM-10:30AM: Abstract Number: 1024

Medical Care Seeking Is Frequent and Associated with Overuse of Low-Value Care for Low Back Pain in Portugal: Results from a Nationwide Population-Based Study

8:30AM-10:30AM: Abstract Number: 1054

Metabolomics as an Innovative Tool for Cardiac Risk Stratification in Patients with Rheumatic Diseases: Results from a Pilot Study

8:30AM-10:30AM: Abstract Number: 1040

Monoclonal Gammopathy in Autoimmune Diseases: Analysis and Follow-up of 160 Cases in a Tertiary Center in China

8:30AM-10:30AM: Abstract Number: 1049

Multimorbidity Differences Between Systemic Lupus Erythematosus Patients and Comparators in Different Age Groups: A Large Nationwide US Study

8:30AM-10:30AM: Abstract Number: 1042

Multimorbidity Prevalence in Systemic Lupus Erythematosus: A Population-Based Study

8:30AM-10:30AM: Abstract Number: 1044

Older Patients with Rheumatic Disease Are Commonly Prescribed Potentially Inappropriate Medications

8:30AM-10:30AM: Abstract Number: 1038

Outcomes of Hydroxychloroquine Screening for Retinopathy in a Cohort of Patients with Rheumatological Conditions

8:30AM-10:30AM: Abstract Number: 1033

Physical Inactivity Among Adults with Specific Chronic Conditions, by Arthritis Status, 49 States and District of Columbia, Behavioral Risk Factor Surveillance System, 2019

8:30AM-10:30AM: Abstract Number: 1043

Prevalence of Multimorbidity in Cutaneous Lupus Erythematosus: A Population-Based Study

8:30AM-10:30AM: Abstract Number: 1023

Racial and Ethnic Distribution of Rheumatic Diseases in Health Systems of the National Patient-Centered Clinical Research Network

8:30AM-10:30AM: Abstract Number: 1034

Racial/ethnic Differences in Lupus Pregnancy Outcomes over 1 Decade: A US National Study

8:30AM-10:30AM: Abstract Number: 1046

Risk of Ocular Comorbidities and Blindness Among Patients with Behçet’s Disease: A Nationwide Population-based Cohort Study in Korea

8:30AM-10:30AM: Abstract Number: 1058

Sex-Specific Associations Between Knee Synovial Fluid Biomarkers and Knee Osteoarthritis Pain

8:30AM-10:30AM: Abstract Number: 1025

Survival of Patients with Idiopathic Inflammatory Myopathy in Slovenia

8:30AM-10:30AM: Abstract Number: 1053

Temporal Trends and Geographic Variations of Premature Mortality Related to Musculoskeletal(MSK) and Connective Tissue Disorders in the United States: A 20-Year Analysis from WONDER Database

8:30AM-10:30AM: Abstract Number: 1060

Temporal Trends of Arthropathies Related Mortality in the United States and Its Regional Variations from 1999-2018

8:30AM-10:30AM: Abstract Number: 1059

The Association of Pain and Sleep in Relation to Depressive Symptoms Among Older Adults with Arthritis

8:30AM-10:30AM: Abstract Number: 1036

The Association of Patient Uncertainty with Mental Health in Systemic Autoimmune Rheumatic Diseases

8:30AM-10:30AM: Abstract Number: 1035

The ELSA-Brasil Musculoskeletal Cohort (ELSA-Brasil MSK): Design, Implementation and Prevalence of Chronic Musculoskeletal Pain and Radiographic Knee Osteoarthritis at Baseline

8:30AM-10:30AM: Abstract Number: 1051

Variance of Joint Space Width Across the Tibiofemoral Joint on Knee Radiographs: A Novel Measure of Structure and Progression

8:30AM-10:30AM: Abstract Number: 1037

Variations in Total Knee Replacement Utilization and Outcomes in USA and Canada: The Role of Geography and Socioeconomic Factors

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].